Headlines

The pioneering prostate cancer drug abiraterone can significantly extend the lives of men with advanced prostate cancer if administered prior to administering chemotherapy, according to phase III clinical trial data.

A phase III study of patients with metastatic colorectal cancer has indicated that FOLFOXIRI chemotherapy, in combination with bevacizumab, is superior to the standard FOLFIRI chemotherapy with bevacizumab.

There is increasing evidence that adolescent and young adult patients with acute lymphoblastic leukemia (ALL) tend to fare better when treated with high-intensity pediatric protocols than standard adult regimens.